The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis

The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis

Bibliographic Details
Main Author:	Şenay Yıldız Çelik
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2017-09-01
Series:	Türk Nöroloji Dergisi
Subjects:	Multiple sclerosis treatment ocrelizumab monoclonal antibody
Online Access:	http://www.tjn.org.tr/jvi.aspx?pdir=tjn&plng=eng&un=TJN-71354

Similar Items

Ocrelizumab as a breakthrogh in multiple sclerosis treatment
by: Marcin Zaniuk, et al.
Published: (2021-05-01)

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01)

OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS
by: E. V. Popova
Published: (2018-02-01)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
by: Frau J, et al.
Published: (2018-04-01)

Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review
by: D. L. Klabukova, et al.
Published: (2018-07-01)

The experience of using ocrelizumab in routine practice
by: E. V. Popova, et al.
Published: (2020-03-01)

Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
by: D. L. Klabukova, et al.
Published: (2018-11-01)

Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
by: Duarte Diana Borges, et al.
Published: (2021-07-01)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
by: Angel P. Sempere, et al.
Published: (2021-01-01)

Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile
by: D. L. Klabukova, et al.
Published: (2019-06-01)

The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis
by: Mohammad Z.I. Asha, et al.
Published: (2021-12-01)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
by: Sridhar Chilimuri, et al.
Published: (2021-03-01)

6-Month Effectiveness Safety and Tolerability of Ocrelizumab and Comparative Safety with Rituximab
by: Moss, Brandon Price
Published: (2020)

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
by: Stefan Gingele, et al.
Published: (2018-12-01)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
by: Despoina Florou, et al.
Published: (2020-10-01)

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
by: Gianmarco Abbadessa, et al.
Published: (2021-08-01)

Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
by: Gabrielle Benesh, BS, et al.
Published: (2021-10-01)

Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis
by: O. V. Boyko, et al.
Published: (2019-03-01)

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol
by: Petra Dirks, et al.
Published: (2020-03-01)

Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment
by: Carla Prezioso, et al.
Published: (2021-08-01)

New drugs for anti-B-cell therapy of multiple sclerosis
by: A. N. Boyko, et al.
Published: (2018-04-01)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
by: Charles A. Roach, et al.
Published: (2021-01-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01)

Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application
by: N. Yu. Lashch
Published: (2020-07-01)

Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue
by: Valeria Koska, et al.
Published: (2021-06-01)

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
by: Elsbernd PM, et al.
Published: (2021-06-01)

A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies
by: Saurabh Kataria, et al.
Published: (2020-12-01)

Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review
by: Katja Schmitz, et al.
Published: (2017-09-01)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
by: Bawa, K., et al.
Published: (2021)

Molecular Interventions towards Multiple Sclerosis Treatment
by: Athanasios Metaxakis, et al.
Published: (2020-05-01)

Use of monoclonal antibodies in patients with multiple sclerosis in the practice of a neurologist
by: N. Yu. Lashch
Published: (2020-03-01)

The Danish Multiple Sclerosis Treatment Register
by: Magyari M, et al.
Published: (2016-10-01)

The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis
by: Paolo Angelo Cortesi, et al.
Published: (2019-07-01)

MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT
by: E. V. Popova
Published: (2017-05-01)

Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)
by: E. V. Popova, et al.
Published: (2014-12-01)

Multiple Sclerosis: Methods of Treatment and Rehabilitation
by: Yuriy Lysenko
Published: (2017-06-01)

Monoclonal Antibodies in Multiple Sclerosis: Present and Future
by: Natalia V. Voge, et al.
Published: (2019-03-01)

Results of Expert Council meeting on modern principles of treatment optimization in patients with relapsing-remitting multiple sclerosis using anti-CD20 monoclonal antibody
by: A. N. Boyko, et al.
Published: (2021-06-01)

Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives
by: Giulia Ceglie, et al.
Published: (2020-07-01)

Immunological Aspects of Approved MS Therapeutics
by: Paulus S. Rommer, et al.
Published: (2019-07-01)